Hematology

Evidence questions anemia plus thrombocytopenia prognosis in primary myelofibrosis, helping oncology pharmacists refine hematology risk stratification.

Ruxolitinib can shape myelofibrosis care, and other drugs' dosing, resistance, and next-generation combinations are under study.

Data from a phase 2 response-adapted trial identify CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

Evolving myeloma therapies and pharmacist-led care reshape outcomes, tackling resistance, toxicity, and personalized treatment sequencing.

Circulating tumor cells detected in peripheral blood may serve as a powerful prognostic biomarker in newly diagnosed multiple myeloma.

FDA approval expands the use of teclistamab plus daratumumab, which significantly improved survival in the MajesTEC-3 trial.

Artificial intelligence helps hematology teams and pharmacists distinguish prefibrotic myelofibrosis from essential thrombocythemia, improving the accuracy of myeloproliferative neoplasm diagnosis and oncology care.

Carfilzomib may boost BCMA CAR T-cell therapy after relapse in multiple myeloma, guiding oncology pharmacists on safer immunotherapy sequencing.

Targeted menin inhibitors offer new hope for patients with difficult-to-treat acute leukemias.

Linvoseltamab joins 3 other bispecific T-cell–engaging antibodies in multiple myeloma, offering deep and durable responses in heavily pretreated patients.

The approval for the oral, fixed-duration chronic lymphocytic leukemia (CLL) regimen was based on results from the phase 3 AMPLIFY trial.

A 4-step pharmacist-led approach improves oral anticoagulant safety and outcomes.

Frontline therapy for DLBCL is evolving with the integration of targeted and cellular therapies, demonstrating promising outcomes.

Tagraxofusp monotherapy in myelofibrosis shows symptom relief with manageable toxicity, as pharmacists can monitor capillary leak syndrome and cytopenias.

Innovent’s trispecific antibody IBI3003 has received FDA fast track designation for R/R MM, supported by early clinical data showing strong efficacy and manageable safety in heavily pretreated and high-risk patients.

RESTORE trial data show investigational elritercept improves myelofibrosis anemia and cytopenias, reduces transfusions, and guides pharmacists on monitoring with ruxolitinib.

Pharmacists unpack CAR T-cell therapy in acute lymphoblastic leukemia, spotlighting obecabtagene autoleucel data and toxicity tips.

Emerging ultraprecision therapies target CALR mutations in myelofibrosis, promising more effective treatments and improved patient outcomes for pharmacists.

Zavabresib receives orphan drug designation for myelofibrosis, offering hope for patients unresponsive to current treatments and enhancing therapeutic options.

Innovative immunotherapy strategies, like linvoseltamab, show promise in treating multiple myeloma, potentially reducing reliance on traditional transplants.

Explore the evolving landscape of myelofibrosis treatment, focusing on personalized therapy, JAK inhibitors, and the role of pharmacists in patient care.

Pharmacists can play a pivotal role in overcoming the many challenges that exist in accessing immunomodulatory drugs in multiple myeloma.

FDA approves mosunetuzumab's subcutaneous formulation, enhancing treatment access for relapsed follicular lymphoma.

Discover the vital role of oncology pharmacists in cancer care, exploring their daily challenges, responsibilities, and impact on patient outcomes.

FDA grants a national priority voucher to teclistamab and daratumumab for relapsed/refractory multiple myeloma, enhancing treatment approval speed.